nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—kidney cancer—sarcoma	0.223	0.509	CtDrD
Erlotinib—lung cancer—sarcoma	0.215	0.491	CtDrD
Erlotinib—EGFR—sarcoma	0.206	1	CbGaD
Erlotinib—CYP1B1—Mitoxantrone—sarcoma	0.0317	0.153	CbGbCtD
Erlotinib—CYP1A1—Dacarbazine—sarcoma	0.0179	0.0868	CbGbCtD
Erlotinib—UGT1A1—Etoposide—sarcoma	0.0173	0.0837	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—sarcoma	0.0168	0.0815	CbGbCtD
Erlotinib—ABCG2—Mitoxantrone—sarcoma	0.0151	0.073	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—sarcoma	0.0136	0.066	CbGbCtD
Erlotinib—ABCG2—Vincristine—sarcoma	0.0104	0.0502	CbGbCtD
Erlotinib—ABCG2—Etoposide—sarcoma	0.0095	0.046	CbGbCtD
Erlotinib—CYP1A2—Dacarbazine—sarcoma	0.008	0.0388	CbGbCtD
Erlotinib—CYP3A4—Thiotepa—sarcoma	0.00757	0.0367	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—sarcoma	0.00648	0.0314	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—sarcoma	0.00607	0.0294	CbGbCtD
Erlotinib—CYP3A5—Vincristine—sarcoma	0.00574	0.0278	CbGbCtD
Erlotinib—ABCB1—Mitoxantrone—sarcoma	0.00543	0.0263	CbGbCtD
Erlotinib—CYP3A5—Etoposide—sarcoma	0.00526	0.0255	CbGbCtD
Erlotinib—STK10—renal vein—sarcoma	0.00523	0.133	CbGeAlD
Erlotinib—CYP2C8—Etoposide—sarcoma	0.00506	0.0245	CbGbCtD
Erlotinib—CYP1A2—Etoposide—sarcoma	0.00392	0.019	CbGbCtD
Erlotinib—ABCB1—Vincristine—sarcoma	0.00374	0.0181	CbGbCtD
Erlotinib—ABCB1—Etoposide—sarcoma	0.00342	0.0166	CbGbCtD
Erlotinib—CYP3A4—Mitoxantrone—sarcoma	0.00325	0.0158	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—sarcoma	0.00234	0.0113	CbGbCtD
Erlotinib—CYP3A4—Vincristine—sarcoma	0.00224	0.0108	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—sarcoma	0.0022	0.0107	CbGbCtD
Erlotinib—CYP3A4—Etoposide—sarcoma	0.00205	0.00994	CbGbCtD
Erlotinib—CYP3A4—Doxorubicin—sarcoma	0.0014	0.00678	CbGbCtD
Erlotinib—Vandetanib—TEK—sarcoma	0.00092	0.267	CrCbGaD
Erlotinib—EGFR—mammary gland—sarcoma	0.000651	0.0166	CbGeAlD
Erlotinib—PIP4K2C—mammary gland—sarcoma	0.000631	0.0161	CbGeAlD
Erlotinib—Vandetanib—PDGFRB—sarcoma	0.000593	0.172	CrCbGaD
Erlotinib—MKNK1—mammary gland—sarcoma	0.000567	0.0144	CbGeAlD
Erlotinib—JAK3—hematopoietic system—sarcoma	0.000539	0.0137	CbGeAlD
Erlotinib—SLK—mammary gland—sarcoma	0.000537	0.0137	CbGeAlD
Erlotinib—JAK3—connective tissue—sarcoma	0.000519	0.0132	CbGeAlD
Erlotinib—Vandetanib—SRC—sarcoma	0.000478	0.139	CrCbGaD
Erlotinib—Vandetanib—KDR—sarcoma	0.000449	0.13	CrCbGaD
Erlotinib—PIP4K2C—myometrium—sarcoma	0.000447	0.0114	CbGeAlD
Erlotinib—ULK3—myometrium—sarcoma	0.000427	0.0109	CbGeAlD
Erlotinib—FLT3—hematopoietic system—sarcoma	0.000425	0.0108	CbGeAlD
Erlotinib—FLT3—connective tissue—sarcoma	0.00041	0.0104	CbGeAlD
Erlotinib—PIP4K2C—seminal vesicle—sarcoma	0.000404	0.0103	CbGeAlD
Erlotinib—MKNK1—myometrium—sarcoma	0.000402	0.0102	CbGeAlD
Erlotinib—ULK3—seminal vesicle—sarcoma	0.000386	0.00983	CbGeAlD
Erlotinib—AURKC—tendon—sarcoma	0.000385	0.00981	CbGeAlD
Erlotinib—SLK—myometrium—sarcoma	0.000381	0.00969	CbGeAlD
Erlotinib—Vandetanib—VEGFA—sarcoma	0.000381	0.11	CrCbGaD
Erlotinib—JAK3—lymphoid tissue—sarcoma	0.00038	0.00966	CbGeAlD
Erlotinib—TNK1—uterus—sarcoma	0.000374	0.00952	CbGeAlD
Erlotinib—HIPK4—testis—sarcoma	0.000374	0.00952	CbGeAlD
Erlotinib—LTK—testis—sarcoma	0.00037	0.00941	CbGeAlD
Erlotinib—ULK3—hematopoietic system—sarcoma	0.000367	0.00934	CbGeAlD
Erlotinib—NR1I2—liver—sarcoma	0.000349	0.0089	CbGeAlD
Erlotinib—MKNK1—hematopoietic system—sarcoma	0.000345	0.00879	CbGeAlD
Erlotinib—SLK—seminal vesicle—sarcoma	0.000344	0.00876	CbGeAlD
Erlotinib—STK10—myometrium—sarcoma	0.000331	0.00843	CbGeAlD
Erlotinib—TNK1—tendon—sarcoma	0.000328	0.00834	CbGeAlD
Erlotinib—SLCO2B1—mammary gland—sarcoma	0.000324	0.00826	CbGeAlD
Erlotinib—ABL1—mammary gland—sarcoma	0.000322	0.00818	CbGeAlD
Erlotinib—Vandetanib—EGFR—sarcoma	0.000321	0.0932	CrCbGaD
Erlotinib—AURKC—testis—sarcoma	0.000319	0.00812	CbGeAlD
Erlotinib—Gefitinib—EGFR—sarcoma	0.000305	0.0885	CrCbGaD
Erlotinib—FLT3—lymphoid tissue—sarcoma	0.000299	0.00762	CbGeAlD
Erlotinib—EGFR—uterus—sarcoma	0.000299	0.00762	CbGeAlD
Erlotinib—ALB—mammary gland—sarcoma	0.000297	0.00755	CbGeAlD
Erlotinib—MAP2K5—myometrium—sarcoma	0.000296	0.00753	CbGeAlD
Erlotinib—JAK3—testis—sarcoma	0.000295	0.00752	CbGeAlD
Erlotinib—EPHA6—testis—sarcoma	0.000295	0.00752	CbGeAlD
Erlotinib—PIP4K2C—cardiac atrium—sarcoma	0.000292	0.00743	CbGeAlD
Erlotinib—STK10—hematopoietic system—sarcoma	0.000284	0.00724	CbGeAlD
Erlotinib—ULK3—cardiac atrium—sarcoma	0.000279	0.00709	CbGeAlD
Erlotinib—ULK3—uterus—sarcoma	0.000277	0.00705	CbGeAlD
Erlotinib—FLT3—bone marrow—sarcoma	0.000273	0.00694	CbGeAlD
Erlotinib—CYP1B1—mammary gland—sarcoma	0.000272	0.00693	CbGeAlD
Erlotinib—TNK1—testis—sarcoma	0.000271	0.00691	CbGeAlD
Erlotinib—ABL2—tendon—sarcoma	0.000269	0.00684	CbGeAlD
Erlotinib—MAP3K19—testis—sarcoma	0.000269	0.00684	CbGeAlD
Erlotinib—UGT1A1—hematopoietic system—sarcoma	0.000269	0.00684	CbGeAlD
Erlotinib—LTK—lymph node—sarcoma	0.000268	0.00682	CbGeAlD
Erlotinib—MAP2K5—seminal vesicle—sarcoma	0.000267	0.0068	CbGeAlD
Erlotinib—MKNK1—cardiac atrium—sarcoma	0.000262	0.00667	CbGeAlD
Erlotinib—TNK1—liver—sarcoma	0.000256	0.00653	CbGeAlD
Erlotinib—PIP4K2C—tendon—sarcoma	0.000254	0.00647	CbGeAlD
Erlotinib—ABL1—Idarubicin—Epirubicin—sarcoma	0.00025	0.173	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—sarcoma	0.00025	0.173	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—sarcoma	0.00025	0.173	CbGdCrCtD
Erlotinib—SLK—cardiac atrium—sarcoma	0.000248	0.00632	CbGeAlD
Erlotinib—SLK—uterus—sarcoma	0.000247	0.00629	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—sarcoma	0.000246	0.00627	CbGeAlD
Erlotinib—MKNK1—lymphoid tissue—sarcoma	0.000243	0.00619	CbGeAlD
Erlotinib—ULK3—tendon—sarcoma	0.000243	0.00618	CbGeAlD
Erlotinib—ULK3—bone marrow—sarcoma	0.000235	0.00599	CbGeAlD
Erlotinib—FLT3—testis—sarcoma	0.000233	0.00593	CbGeAlD
Erlotinib—ABL1—Idarubicin—Doxorubicin—sarcoma	0.000232	0.16	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—sarcoma	0.000232	0.16	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—sarcoma	0.000232	0.16	CbGdCrCtD
Erlotinib—AURKC—lymph node—sarcoma	0.000231	0.00589	CbGeAlD
Erlotinib—ABL1—myometrium—sarcoma	0.000228	0.00581	CbGeAlD
Erlotinib—ABL2—testis—sarcoma	0.000223	0.00566	CbGeAlD
Erlotinib—MKNK1—bone marrow—sarcoma	0.000221	0.00563	CbGeAlD
Erlotinib—FLT3—liver—sarcoma	0.00022	0.00561	CbGeAlD
Erlotinib—ABL1—embryo—sarcoma	0.000219	0.00559	CbGeAlD
Erlotinib—EGFR—testis—sarcoma	0.000217	0.00553	CbGeAlD
Erlotinib—SLK—tendon—sarcoma	0.000216	0.00551	CbGeAlD
Erlotinib—STK10—uterus—sarcoma	0.000215	0.00547	CbGeAlD
Erlotinib—JAK3—lymph node—sarcoma	0.000214	0.00545	CbGeAlD
Erlotinib—PIP4K2C—testis—sarcoma	0.000211	0.00536	CbGeAlD
Erlotinib—ABL2—liver—sarcoma	0.00021	0.00536	CbGeAlD
Erlotinib—SLK—bone marrow—sarcoma	0.00021	0.00534	CbGeAlD
Erlotinib—CYP2C8—mammary gland—sarcoma	0.000209	0.00531	CbGeAlD
Erlotinib—ORM1—hematopoietic system—sarcoma	0.000206	0.00525	CbGeAlD
Erlotinib—ABL1—seminal vesicle—sarcoma	0.000206	0.00525	CbGeAlD
Erlotinib—EGFR—liver—sarcoma	0.000205	0.00523	CbGeAlD
Erlotinib—ULK3—testis—sarcoma	0.000201	0.00512	CbGeAlD
Erlotinib—STK10—lymphoid tissue—sarcoma	0.0002	0.0051	CbGeAlD
Erlotinib—PIP4K2C—liver—sarcoma	0.000199	0.00507	CbGeAlD
Erlotinib—SLCO2B1—hematopoietic system—sarcoma	0.000198	0.00503	CbGeAlD
Erlotinib—TNK1—lymph node—sarcoma	0.000197	0.00501	CbGeAlD
Erlotinib—ABL1—hematopoietic system—sarcoma	0.000196	0.00499	CbGeAlD
Erlotinib—MAP2K5—cardiac atrium—sarcoma	0.000193	0.00491	CbGeAlD
Erlotinib—ULK3—liver—sarcoma	0.00019	0.00484	CbGeAlD
Erlotinib—MKNK1—testis—sarcoma	0.000189	0.00482	CbGeAlD
Erlotinib—ABL1—connective tissue—sarcoma	0.000189	0.0048	CbGeAlD
Erlotinib—STK10—tendon—sarcoma	0.000188	0.00479	CbGeAlD
Erlotinib—STK10—bone marrow—sarcoma	0.000182	0.00464	CbGeAlD
Erlotinib—SLK—testis—sarcoma	0.000179	0.00456	CbGeAlD
Erlotinib—MKNK1—liver—sarcoma	0.000179	0.00455	CbGeAlD
Erlotinib—ABL1—smooth muscle tissue—sarcoma	0.000173	0.00439	CbGeAlD
Erlotinib—ABL1—skin of body—sarcoma	0.00017	0.00434	CbGeAlD
Erlotinib—SLK—liver—sarcoma	0.000169	0.00431	CbGeAlD
Erlotinib—FLT3—lymph node—sarcoma	0.000169	0.0043	CbGeAlD
Erlotinib—MAP2K5—tendon—sarcoma	0.000168	0.00428	CbGeAlD
Erlotinib—CYP1B1—hematopoietic system—sarcoma	0.000166	0.00422	CbGeAlD
Erlotinib—ABL2—lymph node—sarcoma	0.000161	0.00411	CbGeAlD
Erlotinib—CYP1B1—connective tissue—sarcoma	0.00016	0.00407	CbGeAlD
Erlotinib—EGFR—lymph node—sarcoma	0.000157	0.00401	CbGeAlD
Erlotinib—STK10—testis—sarcoma	0.000156	0.00397	CbGeAlD
Erlotinib—PIP4K2C—lymph node—sarcoma	0.000153	0.00388	CbGeAlD
Erlotinib—SLCO2B1—uterus—sarcoma	0.000149	0.0038	CbGeAlD
Erlotinib—ABL1—cardiac atrium—sarcoma	0.000149	0.00379	CbGeAlD
Erlotinib—ABL1—uterus—sarcoma	0.000148	0.00377	CbGeAlD
Erlotinib—STK10—liver—sarcoma	0.000147	0.00375	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—sarcoma	0.000146	0.00372	CbGeAlD
Erlotinib—ULK3—lymph node—sarcoma	0.000146	0.00371	CbGeAlD
Erlotinib—CYP1B1—skin of body—sarcoma	0.000144	0.00367	CbGeAlD
Erlotinib—ABCG2—myometrium—sarcoma	0.000144	0.00366	CbGeAlD
Erlotinib—MAP2K5—testis—sarcoma	0.000139	0.00354	CbGeAlD
Erlotinib—UGT1A1—liver—sarcoma	0.000139	0.00354	CbGeAlD
Erlotinib—ABL1—lymphoid tissue—sarcoma	0.000138	0.00351	CbGeAlD
Erlotinib—MKNK1—lymph node—sarcoma	0.000137	0.00349	CbGeAlD
Erlotinib—ORM1—bone marrow—sarcoma	0.000132	0.00336	CbGeAlD
Erlotinib—MAP2K5—liver—sarcoma	0.000132	0.00335	CbGeAlD
Erlotinib—SLCO2B1—tendon—sarcoma	0.000131	0.00333	CbGeAlD
Erlotinib—ABCG2—seminal vesicle—sarcoma	0.00013	0.00331	CbGeAlD
Erlotinib—SLK—lymph node—sarcoma	0.00013	0.00331	CbGeAlD
Erlotinib—ABL1—tendon—sarcoma	0.00013	0.0033	CbGeAlD
Erlotinib—CYP2C8—hematopoietic system—sarcoma	0.000127	0.00323	CbGeAlD
Erlotinib—ABL1—bone marrow—sarcoma	0.000126	0.0032	CbGeAlD
Erlotinib—CYP1B1—uterus—sarcoma	0.000125	0.00319	CbGeAlD
Erlotinib—CYP1A2—hematopoietic system—sarcoma	0.000119	0.00303	CbGeAlD
Erlotinib—CYP1A1—hematopoietic system—sarcoma	0.000117	0.00299	CbGeAlD
Erlotinib—CYP1B1—lymphoid tissue—sarcoma	0.000117	0.00297	CbGeAlD
Erlotinib—CYP3A5—hematopoietic system—sarcoma	0.000115	0.00292	CbGeAlD
Erlotinib—STK10—lymph node—sarcoma	0.000113	0.00288	CbGeAlD
Erlotinib—CYP1B1—tendon—sarcoma	0.00011	0.00279	CbGeAlD
Erlotinib—SLCO2B1—testis—sarcoma	0.000108	0.00276	CbGeAlD
Erlotinib—ABL1—testis—sarcoma	0.000107	0.00273	CbGeAlD
Erlotinib—ORM1—liver—sarcoma	0.000107	0.00272	CbGeAlD
Erlotinib—SLCO2B1—liver—sarcoma	0.000102	0.00261	CbGeAlD
Erlotinib—CYP1A1—skin of body—sarcoma	0.000102	0.0026	CbGeAlD
Erlotinib—ABL1—liver—sarcoma	0.000101	0.00258	CbGeAlD
Erlotinib—MAP2K5—lymph node—sarcoma	0.000101	0.00257	CbGeAlD
Erlotinib—ALB—testis—sarcoma	9.91e-05	0.00252	CbGeAlD
Erlotinib—ALB—liver—sarcoma	9.37e-05	0.00238	CbGeAlD
Erlotinib—ABCG2—uterus—sarcoma	9.33e-05	0.00238	CbGeAlD
Erlotinib—Decreased appetite—Dactinomycin—sarcoma	9.18e-05	0.00169	CcSEcCtD
Erlotinib—Fatigue—Thiotepa—sarcoma	9.18e-05	0.00169	CcSEcCtD
Erlotinib—Renal impairment—Epirubicin—sarcoma	9.16e-05	0.00169	CcSEcCtD
Erlotinib—Infection—Mitoxantrone—sarcoma	9.13e-05	0.00168	CcSEcCtD
Erlotinib—Dermatitis bullous—Epirubicin—sarcoma	9.12e-05	0.00168	CcSEcCtD
Erlotinib—Fatigue—Dactinomycin—sarcoma	9.11e-05	0.00168	CcSEcCtD
Erlotinib—Constipation—Thiotepa—sarcoma	9.1e-05	0.00167	CcSEcCtD
Erlotinib—Pain—Thiotepa—sarcoma	9.1e-05	0.00167	CcSEcCtD
Erlotinib—CYP1B1—testis—sarcoma	9.09e-05	0.00231	CbGeAlD
Erlotinib—Back pain—Etoposide—sarcoma	9.06e-05	0.00167	CcSEcCtD
Erlotinib—Shock—Mitoxantrone—sarcoma	9.04e-05	0.00166	CcSEcCtD
Erlotinib—Pain—Dactinomycin—sarcoma	9.03e-05	0.00166	CcSEcCtD
Erlotinib—Thrombocytopenia—Mitoxantrone—sarcoma	9e-05	0.00166	CcSEcCtD
Erlotinib—Anorexia—Vincristine—sarcoma	9e-05	0.00166	CcSEcCtD
Erlotinib—Hepatic failure—Doxorubicin—sarcoma	8.98e-05	0.00165	CcSEcCtD
Erlotinib—Skin disorder—Mitoxantrone—sarcoma	8.93e-05	0.00164	CcSEcCtD
Erlotinib—CYP1A1—cardiac atrium—sarcoma	8.9e-05	0.00227	CbGeAlD
Erlotinib—Cerebrovascular accident—Epirubicin—sarcoma	8.9e-05	0.00164	CcSEcCtD
Erlotinib—CYP1A1—uterus—sarcoma	8.86e-05	0.00225	CbGeAlD
Erlotinib—Anorexia—Mitoxantrone—sarcoma	8.76e-05	0.00161	CcSEcCtD
Erlotinib—Renal failure acute—Doxorubicin—sarcoma	8.74e-05	0.00161	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Epirubicin—sarcoma	8.72e-05	0.0016	CcSEcCtD
Erlotinib—Gastrointestinal pain—Thiotepa—sarcoma	8.7e-05	0.0016	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dactinomycin—sarcoma	8.64e-05	0.00159	CcSEcCtD
Erlotinib—CYP3A4—hematopoietic system—sarcoma	8.6e-05	0.00219	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Vincristine—sarcoma	8.6e-05	0.00158	CcSEcCtD
Erlotinib—CYP1B1—liver—sarcoma	8.59e-05	0.00219	CbGeAlD
Erlotinib—Insomnia—Vincristine—sarcoma	8.54e-05	0.00157	CcSEcCtD
Erlotinib—Renal impairment—Doxorubicin—sarcoma	8.48e-05	0.00156	CcSEcCtD
Erlotinib—CYP2D6—hematopoietic system—sarcoma	8.47e-05	0.00216	CbGeAlD
Erlotinib—Dermatitis bullous—Doxorubicin—sarcoma	8.44e-05	0.00155	CcSEcCtD
Erlotinib—Abdominal pain—Thiotepa—sarcoma	8.41e-05	0.00155	CcSEcCtD
Erlotinib—Body temperature increased—Thiotepa—sarcoma	8.41e-05	0.00155	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	8.37e-05	0.00154	CcSEcCtD
Erlotinib—Body temperature increased—Dactinomycin—sarcoma	8.35e-05	0.00154	CcSEcCtD
Erlotinib—Abdominal pain—Dactinomycin—sarcoma	8.35e-05	0.00154	CcSEcCtD
Erlotinib—Loss of consciousness—Etoposide—sarcoma	8.23e-05	0.00151	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—sarcoma	8.23e-05	0.00151	CcSEcCtD
Erlotinib—Decreased appetite—Vincristine—sarcoma	8.2e-05	0.00151	CcSEcCtD
Erlotinib—Dyspnoea—Mitoxantrone—sarcoma	8.19e-05	0.00151	CcSEcCtD
Erlotinib—ORM1—lymph node—sarcoma	8.19e-05	0.00208	CbGeAlD
Erlotinib—Cough—Etoposide—sarcoma	8.17e-05	0.0015	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Vincristine—sarcoma	8.15e-05	0.0015	CcSEcCtD
Erlotinib—Fatigue—Vincristine—sarcoma	8.14e-05	0.0015	CcSEcCtD
Erlotinib—Dehydration—Epirubicin—sarcoma	8.11e-05	0.00149	CcSEcCtD
Erlotinib—Dyspepsia—Mitoxantrone—sarcoma	8.09e-05	0.00149	CcSEcCtD
Erlotinib—Pain—Vincristine—sarcoma	8.07e-05	0.00148	CcSEcCtD
Erlotinib—Constipation—Vincristine—sarcoma	8.07e-05	0.00148	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	8.07e-05	0.00148	CcSEcCtD
Erlotinib—Dry skin—Epirubicin—sarcoma	7.99e-05	0.00147	CcSEcCtD
Erlotinib—Decreased appetite—Mitoxantrone—sarcoma	7.99e-05	0.00147	CcSEcCtD
Erlotinib—Chest pain—Etoposide—sarcoma	7.98e-05	0.00147	CcSEcCtD
Erlotinib—Hypokalaemia—Epirubicin—sarcoma	7.94e-05	0.00146	CcSEcCtD
Erlotinib—Fatigue—Mitoxantrone—sarcoma	7.92e-05	0.00146	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	7.92e-05	0.00146	CcSEcCtD
Erlotinib—ABCG2—bone marrow—sarcoma	7.92e-05	0.00202	CbGeAlD
Erlotinib—Constipation—Mitoxantrone—sarcoma	7.86e-05	0.00145	CcSEcCtD
Erlotinib—Pain—Mitoxantrone—sarcoma	7.86e-05	0.00145	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Epirubicin—sarcoma	7.85e-05	0.00144	CcSEcCtD
Erlotinib—SLCO2B1—lymph node—sarcoma	7.85e-05	0.002	CbGeAlD
Erlotinib—ABL1—lymph node—sarcoma	7.78e-05	0.00198	CbGeAlD
Erlotinib—Gastrointestinal pain—Vincristine—sarcoma	7.72e-05	0.00142	CcSEcCtD
Erlotinib—Gastritis—Epirubicin—sarcoma	7.72e-05	0.00142	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—sarcoma	7.69e-05	0.00141	CcSEcCtD
Erlotinib—Asthenia—Thiotepa—sarcoma	7.64e-05	0.0014	CcSEcCtD
Erlotinib—Infection—Etoposide—sarcoma	7.6e-05	0.0014	CcSEcCtD
Erlotinib—Asthenia—Dactinomycin—sarcoma	7.58e-05	0.00139	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—sarcoma	7.54e-05	0.00139	CcSEcCtD
Erlotinib—Pruritus—Thiotepa—sarcoma	7.53e-05	0.00139	CcSEcCtD
Erlotinib—Gastrointestinal pain—Mitoxantrone—sarcoma	7.52e-05	0.00138	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—sarcoma	7.5e-05	0.00138	CcSEcCtD
Erlotinib—Thrombocytopenia—Etoposide—sarcoma	7.49e-05	0.00138	CcSEcCtD
Erlotinib—Abdominal pain—Vincristine—sarcoma	7.46e-05	0.00137	CcSEcCtD
Erlotinib—Body temperature increased—Vincristine—sarcoma	7.46e-05	0.00137	CcSEcCtD
Erlotinib—Skin disorder—Etoposide—sarcoma	7.43e-05	0.00137	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—sarcoma	7.4e-05	0.00136	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—sarcoma	7.39e-05	0.00136	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—sarcoma	7.34e-05	0.00135	CcSEcCtD
Erlotinib—Anorexia—Etoposide—sarcoma	7.29e-05	0.00134	CcSEcCtD
Erlotinib—Diarrhoea—Thiotepa—sarcoma	7.28e-05	0.00134	CcSEcCtD
Erlotinib—Abdominal pain—Mitoxantrone—sarcoma	7.27e-05	0.00134	CcSEcCtD
Erlotinib—Body temperature increased—Mitoxantrone—sarcoma	7.27e-05	0.00134	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—sarcoma	7.27e-05	0.00134	CcSEcCtD
Erlotinib—Diarrhoea—Dactinomycin—sarcoma	7.23e-05	0.00133	CcSEcCtD
Erlotinib—ALB—lymph node—sarcoma	7.18e-05	0.00183	CbGeAlD
Erlotinib—Gastritis—Doxorubicin—sarcoma	7.14e-05	0.00131	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	7.12e-05	0.00131	CcSEcCtD
Erlotinib—ABCB1—myometrium—sarcoma	7.09e-05	0.00181	CbGeAlD
Erlotinib—Neutropenia—Epirubicin—sarcoma	7.05e-05	0.0013	CcSEcCtD
Erlotinib—Dizziness—Thiotepa—sarcoma	7.04e-05	0.00129	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—sarcoma	6.97e-05	0.00128	CcSEcCtD
Erlotinib—CYP2C8—testis—sarcoma	6.96e-05	0.00177	CbGeAlD
Erlotinib—Pancreatitis—Doxorubicin—sarcoma	6.84e-05	0.00126	CcSEcCtD
Erlotinib—ABCB1—embryo—sarcoma	6.82e-05	0.00174	CbGeAlD
Erlotinib—Weight decreased—Epirubicin—sarcoma	6.82e-05	0.00125	CcSEcCtD
Erlotinib—Dyspnoea—Etoposide—sarcoma	6.82e-05	0.00125	CcSEcCtD
Erlotinib—Asthenia—Vincristine—sarcoma	6.77e-05	0.00125	CcSEcCtD
Erlotinib—ABCG2—testis—sarcoma	6.77e-05	0.00172	CbGeAlD
Erlotinib—Vomiting—Thiotepa—sarcoma	6.77e-05	0.00125	CcSEcCtD
Erlotinib—Pneumonia—Epirubicin—sarcoma	6.76e-05	0.00124	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—sarcoma	6.72e-05	0.00124	CcSEcCtD
Erlotinib—Infestation—Epirubicin—sarcoma	6.72e-05	0.00124	CcSEcCtD
Erlotinib—Vomiting—Dactinomycin—sarcoma	6.72e-05	0.00124	CcSEcCtD
Erlotinib—Rash—Thiotepa—sarcoma	6.71e-05	0.00123	CcSEcCtD
Erlotinib—Dermatitis—Thiotepa—sarcoma	6.7e-05	0.00123	CcSEcCtD
Erlotinib—Headache—Thiotepa—sarcoma	6.67e-05	0.00123	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—sarcoma	6.66e-05	0.00123	CcSEcCtD
Erlotinib—Rash—Dactinomycin—sarcoma	6.66e-05	0.00123	CcSEcCtD
Erlotinib—Decreased appetite—Etoposide—sarcoma	6.65e-05	0.00122	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—sarcoma	6.61e-05	0.00122	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Etoposide—sarcoma	6.6e-05	0.00121	CcSEcCtD
Erlotinib—Asthenia—Mitoxantrone—sarcoma	6.59e-05	0.00121	CcSEcCtD
Erlotinib—Fatigue—Etoposide—sarcoma	6.59e-05	0.00121	CcSEcCtD
Erlotinib—CYP1B1—lymph node—sarcoma	6.59e-05	0.00168	CbGeAlD
Erlotinib—Neuropathy peripheral—Epirubicin—sarcoma	6.59e-05	0.00121	CcSEcCtD
Erlotinib—CYP2C8—liver—sarcoma	6.58e-05	0.00168	CbGeAlD
Erlotinib—Stomatitis—Epirubicin—sarcoma	6.55e-05	0.00121	CcSEcCtD
Erlotinib—Pain—Etoposide—sarcoma	6.54e-05	0.0012	CcSEcCtD
Erlotinib—Constipation—Etoposide—sarcoma	6.54e-05	0.0012	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—sarcoma	6.53e-05	0.0012	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—sarcoma	6.52e-05	0.0012	CcSEcCtD
Erlotinib—Diarrhoea—Vincristine—sarcoma	6.46e-05	0.00119	CcSEcCtD
Erlotinib—ABCB1—seminal vesicle—sarcoma	6.41e-05	0.00163	CbGeAlD
Erlotinib—ABCG2—liver—sarcoma	6.4e-05	0.00163	CbGeAlD
Erlotinib—Hepatobiliary disease—Epirubicin—sarcoma	6.36e-05	0.00117	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—sarcoma	6.34e-05	0.00117	CcSEcCtD
Erlotinib—Nausea—Thiotepa—sarcoma	6.32e-05	0.00116	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—sarcoma	6.31e-05	0.00116	CcSEcCtD
Erlotinib—Diarrhoea—Mitoxantrone—sarcoma	6.29e-05	0.00116	CcSEcCtD
Erlotinib—Nausea—Dactinomycin—sarcoma	6.27e-05	0.00115	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—sarcoma	6.25e-05	0.00115	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—sarcoma	6.25e-05	0.00115	CcSEcCtD
Erlotinib—Dizziness—Vincristine—sarcoma	6.24e-05	0.00115	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—sarcoma	6.22e-05	0.00114	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—sarcoma	6.22e-05	0.00114	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	6.16e-05	0.00113	CcSEcCtD
Erlotinib—CYP1A2—liver—sarcoma	6.16e-05	0.00157	CbGeAlD
Erlotinib—Renal failure—Doxorubicin—sarcoma	6.11e-05	0.00112	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—sarcoma	6.09e-05	0.00112	CcSEcCtD
Erlotinib—ABCB1—hematopoietic system—sarcoma	6.09e-05	0.00155	CbGeAlD
Erlotinib—CYP1A1—liver—sarcoma	6.08e-05	0.00155	CbGeAlD
Erlotinib—Haemoglobin—Epirubicin—sarcoma	6.06e-05	0.00112	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—sarcoma	6.06e-05	0.00111	CcSEcCtD
Erlotinib—Body temperature increased—Etoposide—sarcoma	6.04e-05	0.00111	CcSEcCtD
Erlotinib—Abdominal pain—Etoposide—sarcoma	6.04e-05	0.00111	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—sarcoma	6.04e-05	0.00111	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—sarcoma	6.03e-05	0.00111	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—sarcoma	6.03e-05	0.00111	CcSEcCtD
Erlotinib—Vomiting—Vincristine—sarcoma	6e-05	0.0011	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—sarcoma	5.96e-05	0.0011	CcSEcCtD
Erlotinib—Rash—Vincristine—sarcoma	5.95e-05	0.00109	CcSEcCtD
Erlotinib—Dermatitis—Vincristine—sarcoma	5.95e-05	0.00109	CcSEcCtD
Erlotinib—CYP3A5—liver—sarcoma	5.94e-05	0.00151	CbGeAlD
Erlotinib—Connective tissue disorder—Epirubicin—sarcoma	5.93e-05	0.00109	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—sarcoma	5.91e-05	0.00109	CcSEcCtD
Erlotinib—Headache—Vincristine—sarcoma	5.91e-05	0.00109	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—sarcoma	5.88e-05	0.00108	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—sarcoma	5.86e-05	0.00108	CcSEcCtD
Erlotinib—Vomiting—Mitoxantrone—sarcoma	5.84e-05	0.00108	CcSEcCtD
Erlotinib—Rash—Mitoxantrone—sarcoma	5.8e-05	0.00107	CcSEcCtD
Erlotinib—Dermatitis—Mitoxantrone—sarcoma	5.79e-05	0.00107	CcSEcCtD
Erlotinib—Headache—Mitoxantrone—sarcoma	5.76e-05	0.00106	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—sarcoma	5.7e-05	0.00105	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—sarcoma	5.64e-05	0.00104	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—sarcoma	5.61e-05	0.00103	CcSEcCtD
Erlotinib—Nausea—Vincristine—sarcoma	5.61e-05	0.00103	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—sarcoma	5.58e-05	0.00103	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—sarcoma	5.58e-05	0.00103	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—sarcoma	5.51e-05	0.00101	CcSEcCtD
Erlotinib—Asthenia—Etoposide—sarcoma	5.49e-05	0.00101	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—sarcoma	5.48e-05	0.00101	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—sarcoma	5.47e-05	0.00101	CcSEcCtD
Erlotinib—Nausea—Mitoxantrone—sarcoma	5.46e-05	0.001	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—sarcoma	5.44e-05	0.001	CcSEcCtD
Erlotinib—Chills—Epirubicin—sarcoma	5.41e-05	0.000996	CcSEcCtD
Erlotinib—Pruritus—Etoposide—sarcoma	5.41e-05	0.000995	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—sarcoma	5.39e-05	0.000991	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—sarcoma	5.33e-05	0.000981	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—sarcoma	5.28e-05	0.000972	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—sarcoma	5.28e-05	0.000971	CcSEcCtD
Erlotinib—Erythema—Epirubicin—sarcoma	5.25e-05	0.000966	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—sarcoma	5.25e-05	0.000966	CcSEcCtD
Erlotinib—Diarrhoea—Etoposide—sarcoma	5.23e-05	0.000962	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—sarcoma	5.22e-05	0.00096	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—sarcoma	5.17e-05	0.000952	CcSEcCtD
Erlotinib—Back pain—Epirubicin—sarcoma	5.08e-05	0.000935	CcSEcCtD
Erlotinib—Dizziness—Etoposide—sarcoma	5.06e-05	0.00093	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—sarcoma	5.03e-05	0.000925	CcSEcCtD
Erlotinib—Chills—Doxorubicin—sarcoma	5.01e-05	0.000921	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—sarcoma	4.99e-05	0.000917	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—sarcoma	4.93e-05	0.000907	CcSEcCtD
Erlotinib—ABCG2—lymph node—sarcoma	4.91e-05	0.00125	CbGeAlD
Erlotinib—Mental disorder—Doxorubicin—sarcoma	4.89e-05	0.0009	CcSEcCtD
Erlotinib—Vomiting—Etoposide—sarcoma	4.86e-05	0.000894	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—sarcoma	4.86e-05	0.000894	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—sarcoma	4.86e-05	0.000894	CcSEcCtD
Erlotinib—Rash—Etoposide—sarcoma	4.82e-05	0.000887	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—sarcoma	4.82e-05	0.000886	CcSEcCtD
Erlotinib—Headache—Etoposide—sarcoma	4.79e-05	0.000881	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—sarcoma	4.79e-05	0.000881	CcSEcCtD
Erlotinib—Syncope—Epirubicin—sarcoma	4.71e-05	0.000866	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—sarcoma	4.7e-05	0.000865	CcSEcCtD
Erlotinib—CYP1A1—lymph node—sarcoma	4.66e-05	0.00119	CbGeAlD
Erlotinib—CYP2D6—testis—sarcoma	4.64e-05	0.00118	CbGeAlD
Erlotinib—Loss of consciousness—Epirubicin—sarcoma	4.62e-05	0.000849	CcSEcCtD
Erlotinib—ABCB1—uterus—sarcoma	4.6e-05	0.00117	CbGeAlD
Erlotinib—Cough—Epirubicin—sarcoma	4.58e-05	0.000843	CcSEcCtD
Erlotinib—Nausea—Etoposide—sarcoma	4.54e-05	0.000836	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—sarcoma	4.47e-05	0.000822	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—sarcoma	4.47e-05	0.000822	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—sarcoma	4.47e-05	0.000822	CcSEcCtD
Erlotinib—CYP3A4—liver—sarcoma	4.46e-05	0.00113	CbGeAlD
Erlotinib—Anxiety—Epirubicin—sarcoma	4.46e-05	0.00082	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.44e-05	0.000817	CcSEcCtD
Erlotinib—CYP2D6—liver—sarcoma	4.39e-05	0.00112	CbGeAlD
Erlotinib—Syncope—Doxorubicin—sarcoma	4.36e-05	0.000802	CcSEcCtD
Erlotinib—ABCB1—lymphoid tissue—sarcoma	4.29e-05	0.00109	CbGeAlD
Erlotinib—Oedema—Epirubicin—sarcoma	4.29e-05	0.000788	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—sarcoma	4.27e-05	0.000786	CcSEcCtD
Erlotinib—Infection—Epirubicin—sarcoma	4.26e-05	0.000783	CcSEcCtD
Erlotinib—Cough—Doxorubicin—sarcoma	4.24e-05	0.00078	CcSEcCtD
Erlotinib—Shock—Epirubicin—sarcoma	4.22e-05	0.000776	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—sarcoma	4.2e-05	0.000773	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—sarcoma	4.2e-05	0.000772	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—sarcoma	4.16e-05	0.000766	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—sarcoma	4.14e-05	0.000761	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—sarcoma	4.14e-05	0.000761	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—sarcoma	4.14e-05	0.000761	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—sarcoma	4.12e-05	0.000758	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.11e-05	0.000756	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—sarcoma	4.09e-05	0.000752	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—sarcoma	3.97e-05	0.00073	CcSEcCtD
Erlotinib—Infection—Doxorubicin—sarcoma	3.94e-05	0.000725	CcSEcCtD
Erlotinib—ABCB1—bone marrow—sarcoma	3.9e-05	0.000994	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Epirubicin—sarcoma	3.9e-05	0.000718	CcSEcCtD
Erlotinib—Shock—Doxorubicin—sarcoma	3.9e-05	0.000718	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—sarcoma	3.89e-05	0.000715	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—sarcoma	3.88e-05	0.000714	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—sarcoma	3.88e-05	0.000713	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—sarcoma	3.85e-05	0.000709	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—sarcoma	3.82e-05	0.000703	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—sarcoma	3.78e-05	0.000695	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—sarcoma	3.77e-05	0.000694	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—sarcoma	3.73e-05	0.000685	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—sarcoma	3.7e-05	0.000681	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—sarcoma	3.7e-05	0.00068	CcSEcCtD
Erlotinib—Pain—Epirubicin—sarcoma	3.66e-05	0.000674	CcSEcCtD
Erlotinib—Constipation—Epirubicin—sarcoma	3.66e-05	0.000674	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—sarcoma	3.61e-05	0.000665	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—sarcoma	3.59e-05	0.00066	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—sarcoma	3.54e-05	0.00065	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—sarcoma	3.5e-05	0.000645	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—sarcoma	3.49e-05	0.000642	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—sarcoma	3.45e-05	0.000634	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—sarcoma	3.42e-05	0.00063	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—sarcoma	3.42e-05	0.000629	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—sarcoma	3.39e-05	0.000624	CcSEcCtD
Erlotinib—Pain—Doxorubicin—sarcoma	3.39e-05	0.000624	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—sarcoma	3.39e-05	0.000623	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—sarcoma	3.39e-05	0.000623	CcSEcCtD
Erlotinib—ABCB1—testis—sarcoma	3.34e-05	0.00085	CbGeAlD
Erlotinib—Gastrointestinal pain—Doxorubicin—sarcoma	3.24e-05	0.000597	CcSEcCtD
Erlotinib—ABCB1—liver—sarcoma	3.16e-05	0.000803	CbGeAlD
Erlotinib—Body temperature increased—Doxorubicin—sarcoma	3.13e-05	0.000577	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—sarcoma	3.13e-05	0.000577	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—sarcoma	3.07e-05	0.000566	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—sarcoma	3.03e-05	0.000558	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—sarcoma	2.93e-05	0.000539	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—sarcoma	2.85e-05	0.000523	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—sarcoma	2.83e-05	0.000521	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—sarcoma	2.81e-05	0.000516	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—sarcoma	2.72e-05	0.000501	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—sarcoma	2.71e-05	0.000499	CcSEcCtD
Erlotinib—Rash—Epirubicin—sarcoma	2.7e-05	0.000497	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—sarcoma	2.7e-05	0.000497	CcSEcCtD
Erlotinib—Headache—Epirubicin—sarcoma	2.68e-05	0.000494	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—sarcoma	2.62e-05	0.000482	CcSEcCtD
Erlotinib—Nausea—Epirubicin—sarcoma	2.55e-05	0.000468	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—sarcoma	2.52e-05	0.000464	CcSEcCtD
Erlotinib—Rash—Doxorubicin—sarcoma	2.5e-05	0.00046	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—sarcoma	2.5e-05	0.00046	CcSEcCtD
Erlotinib—Headache—Doxorubicin—sarcoma	2.48e-05	0.000457	CcSEcCtD
Erlotinib—ABCB1—lymph node—sarcoma	2.42e-05	0.000616	CbGeAlD
Erlotinib—Nausea—Doxorubicin—sarcoma	2.36e-05	0.000433	CcSEcCtD
Erlotinib—EGFR—Signaling by NGF—NRAS—sarcoma	8.46e-06	0.000167	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—HRAS—sarcoma	8.41e-06	0.000166	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL2—sarcoma	8.38e-06	0.000165	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ATF1—sarcoma	8.36e-06	0.000165	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ENO2—sarcoma	8.23e-06	0.000162	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP2—sarcoma	8.19e-06	0.000162	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—HBA1—sarcoma	8.18e-06	0.000161	CbGpPWpGaD
Erlotinib—MKNK1—Disease—SRC—sarcoma	8.17e-06	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KIT—sarcoma	8.17e-06	0.000161	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—EGFR—sarcoma	8.16e-06	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Disease—PLCG1—sarcoma	8.12e-06	0.00016	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	8.05e-06	0.000159	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—SRC—sarcoma	7.96e-06	0.000157	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IGF1R—sarcoma	7.9e-06	0.000156	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NRAS—sarcoma	7.86e-06	0.000155	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	7.86e-06	0.000155	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KIT—sarcoma	7.84e-06	0.000155	CbGpPWpGaD
Erlotinib—EGFR—Disease—CXCR4—sarcoma	7.8e-06	0.000154	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	7.77e-06	0.000153	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CREB1—sarcoma	7.77e-06	0.000153	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VEGFA—sarcoma	7.75e-06	0.000153	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—KRAS—sarcoma	7.71e-06	0.000152	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—NRAS—sarcoma	7.66e-06	0.000151	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL2—sarcoma	7.65e-06	0.000151	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KDR—sarcoma	7.63e-06	0.000151	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MDM2—sarcoma	7.53e-06	0.000149	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FOXO1—sarcoma	7.52e-06	0.000148	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PDGFRB—sarcoma	7.51e-06	0.000148	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ENO2—sarcoma	7.49e-06	0.000148	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PLCG1—sarcoma	7.49e-06	0.000148	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IL2—sarcoma	7.47e-06	0.000147	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CREB1—sarcoma	7.47e-06	0.000147	CbGpPWpGaD
Erlotinib—JAK3—Immune System—JUN—sarcoma	7.44e-06	0.000147	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—HBA1—sarcoma	7.44e-06	0.000147	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PDGFRA—sarcoma	7.39e-06	0.000146	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CTNNB1—sarcoma	7.39e-06	0.000146	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—CTNNB1—sarcoma	7.35e-06	0.000145	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MDM2—sarcoma	7.34e-06	0.000145	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MYC—sarcoma	7.33e-06	0.000145	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FOXO1—sarcoma	7.31e-06	0.000144	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PDGFRB—sarcoma	7.29e-06	0.000144	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KRAS—sarcoma	7.28e-06	0.000144	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFC—sarcoma	7.24e-06	0.000143	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PDGFRA—sarcoma	7.18e-06	0.000142	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EGFR—sarcoma	7.17e-06	0.000141	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	7.13e-06	0.000141	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KIT—sarcoma	7.03e-06	0.000139	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—NRAS—sarcoma	7.03e-06	0.000139	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—MYC—sarcoma	7e-06	0.000138	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PLCG1—sarcoma	6.98e-06	0.000138	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	6.85e-06	0.000135	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	6.83e-06	0.000135	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	6.78e-06	0.000134	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KRAS—sarcoma	6.77e-06	0.000134	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CREB1—sarcoma	6.69e-06	0.000132	CbGpPWpGaD
Erlotinib—JAK3—Immune System—SRC—sarcoma	6.68e-06	0.000132	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—SRC—sarcoma	6.65e-06	0.000131	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—KRAS—sarcoma	6.59e-06	0.00013	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL2—sarcoma	6.56e-06	0.000129	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—HRAS—sarcoma	6.55e-06	0.000129	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—JUN—sarcoma	6.54e-06	0.000129	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—SRC—sarcoma	6.52e-06	0.000129	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CTNNB1—sarcoma	6.49e-06	0.000128	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VEGFA—sarcoma	6.47e-06	0.000128	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MDM2—sarcoma	6.43e-06	0.000127	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NRAS—sarcoma	6.42e-06	0.000127	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EGFR—sarcoma	6.41e-06	0.000126	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCND1—sarcoma	6.4e-06	0.000126	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—NRAS—sarcoma	6.39e-06	0.000126	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—JUN—sarcoma	6.38e-06	0.000126	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PLCG1—sarcoma	6.35e-06	0.000125	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VEGFA—sarcoma	6.35e-06	0.000125	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CTNNB1—sarcoma	6.33e-06	0.000125	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CTNNB1—sarcoma	6.28e-06	0.000124	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NRAS—sarcoma	6.27e-06	0.000124	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FOXO1—sarcoma	6.24e-06	0.000123	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PDGFRB—sarcoma	6.23e-06	0.000123	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	6.23e-06	0.000123	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KDR—sarcoma	6.22e-06	0.000123	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—HRAS—sarcoma	6.19e-06	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—MDM2—sarcoma	6.18e-06	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PDGFRA—sarcoma	6.13e-06	0.000121	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	6.13e-06	0.000121	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	6.06e-06	0.00012	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—KRAS—sarcoma	6.05e-06	0.000119	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	5.97e-06	0.000118	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—SRC—sarcoma	5.87e-06	0.000116	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EGFR—sarcoma	5.85e-06	0.000115	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EGFR—sarcoma	5.82e-06	0.000115	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FLT1—sarcoma	5.79e-06	0.000114	CbGpPWpGaD
Erlotinib—EGFR—Disease—FOXO1—sarcoma	5.76e-06	0.000114	CbGpPWpGaD
Erlotinib—EGFR—Disease—PDGFRB—sarcoma	5.75e-06	0.000114	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HRAS—sarcoma	5.75e-06	0.000114	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KIT—sarcoma	5.73e-06	0.000113	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—SRC—sarcoma	5.72e-06	0.000113	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PLCG1—sarcoma	5.69e-06	0.000112	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—SRC—sarcoma	5.68e-06	0.000112	CbGpPWpGaD
Erlotinib—EGFR—Disease—PDGFRA—sarcoma	5.66e-06	0.000112	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NRAS—sarcoma	5.65e-06	0.000111	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—HRAS—sarcoma	5.6e-06	0.00011	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—JUN—sarcoma	5.59e-06	0.00011	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—sarcoma	5.58e-06	0.00011	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KIT—sarcoma	5.57e-06	0.00011	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CTNNB1—sarcoma	5.55e-06	0.000109	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MDM2—sarcoma	5.54e-06	0.000109	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—sarcoma	5.53e-06	0.000109	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KRAS—sarcoma	5.53e-06	0.000109	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NRAS—sarcoma	5.51e-06	0.000109	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—KRAS—sarcoma	5.5e-06	0.000109	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.49e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCR4—sarcoma	5.47e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—NRAS—sarcoma	5.46e-06	0.000108	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CREB1—sarcoma	5.46e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ATF1—sarcoma	5.4e-06	0.000107	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—KRAS—sarcoma	5.4e-06	0.000106	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.37e-06	0.000106	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ENO2—sarcoma	5.36e-06	0.000106	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—HBA1—sarcoma	5.33e-06	0.000105	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CREB1—sarcoma	5.3e-06	0.000105	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—sarcoma	5.14e-06	0.000101	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—sarcoma	5.14e-06	0.000101	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MYC—sarcoma	5.13e-06	0.000101	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	5.08e-06	0.0001	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ENO2—sarcoma	5.07e-06	0.0001	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—HBA1—sarcoma	5.03e-06	9.93e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—sarcoma	5.02e-06	9.9e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—SRC—sarcoma	5.01e-06	9.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CREB1—sarcoma	4.96e-06	9.78e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL2—sarcoma	4.95e-06	9.76e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KRAS—sarcoma	4.86e-06	9.59e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NRAS—sarcoma	4.82e-06	9.52e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCND1—sarcoma	4.82e-06	9.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—SRC—sarcoma	4.82e-06	9.5e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—JUN—sarcoma	4.81e-06	9.5e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—sarcoma	4.8e-06	9.46e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CTNNB1—sarcoma	4.78e-06	9.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KIT—sarcoma	4.76e-06	9.39e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KRAS—sarcoma	4.74e-06	9.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—KRAS—sarcoma	4.7e-06	9.28e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—sarcoma	4.7e-06	9.27e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—sarcoma	4.68e-06	9.23e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ENO2—sarcoma	4.65e-06	9.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NRAS—sarcoma	4.63e-06	9.14e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ENO2—sarcoma	4.62e-06	9.11e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—HBA1—sarcoma	4.62e-06	9.11e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—HBA1—sarcoma	4.59e-06	9.06e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—sarcoma	4.59e-06	9.05e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PLCG1—sarcoma	4.55e-06	8.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CREB1—sarcoma	4.53e-06	8.93e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MDM2—sarcoma	4.51e-06	8.91e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.51e-06	8.9e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KIT—sarcoma	4.39e-06	8.67e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MDM2—sarcoma	4.38e-06	8.65e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SRC—sarcoma	4.32e-06	8.52e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PLCG1—sarcoma	4.3e-06	8.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1R—sarcoma	4.24e-06	8.37e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—sarcoma	4.21e-06	8.31e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—sarcoma	4.2e-06	8.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CREB1—sarcoma	4.18e-06	8.25e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NRAS—sarcoma	4.15e-06	8.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—sarcoma	4.15e-06	8.19e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—sarcoma	4.13e-06	8.15e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ENO2—sarcoma	4.05e-06	7.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FOXO1—sarcoma	4.04e-06	7.96e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—sarcoma	4.03e-06	7.96e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PDGFRB—sarcoma	4.03e-06	7.95e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—sarcoma	4.03e-06	7.95e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HBA1—sarcoma	4.02e-06	7.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—sarcoma	4e-06	7.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—sarcoma	3.99e-06	7.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PDGFRA—sarcoma	3.97e-06	7.83e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PLCG1—sarcoma	3.94e-06	7.78e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCND1—sarcoma	3.93e-06	7.76e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—JUN—sarcoma	3.92e-06	7.74e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PLCG1—sarcoma	3.92e-06	7.73e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—sarcoma	3.92e-06	7.73e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CTNNB1—sarcoma	3.89e-06	7.68e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—sarcoma	3.87e-06	7.63e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO2—sarcoma	3.81e-06	7.52e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—JUN—sarcoma	3.81e-06	7.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HBA1—sarcoma	3.79e-06	7.48e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—sarcoma	3.78e-06	7.47e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTNNB1—sarcoma	3.78e-06	7.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MDM2—sarcoma	3.75e-06	7.39e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—sarcoma	3.68e-06	7.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—sarcoma	3.66e-06	7.23e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—sarcoma	3.57e-06	7.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—sarcoma	3.53e-06	6.96e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SRC—sarcoma	3.52e-06	6.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MDM2—sarcoma	3.46e-06	6.82e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PLCG1—sarcoma	3.43e-06	6.77e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—sarcoma	3.43e-06	6.76e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SRC—sarcoma	3.42e-06	6.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—sarcoma	3.39e-06	6.69e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—sarcoma	3.39e-06	6.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—sarcoma	3.35e-06	6.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KDR—sarcoma	3.34e-06	6.59e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—sarcoma	3.29e-06	6.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—JUN—sarcoma	3.26e-06	6.42e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PLCG1—sarcoma	3.24e-06	6.38e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—sarcoma	3.23e-06	6.38e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO2—sarcoma	3.23e-06	6.37e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HBA1—sarcoma	3.21e-06	6.33e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SRC—sarcoma	3.21e-06	6.33e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—sarcoma	3.18e-06	6.27e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—sarcoma	3.15e-06	6.22e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—sarcoma	3.13e-06	6.17e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—sarcoma	3.09e-06	6.09e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—sarcoma	3.08e-06	6.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIT—sarcoma	3.08e-06	6.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—sarcoma	3.08e-06	6.07e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—sarcoma	3.04e-06	5.99e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—sarcoma	3e-06	5.91e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—sarcoma	2.98e-06	5.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CREB1—sarcoma	2.93e-06	5.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SRC—sarcoma	2.92e-06	5.76e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—sarcoma	2.91e-06	5.75e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—sarcoma	2.83e-06	5.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—sarcoma	2.81e-06	5.54e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLCG1—sarcoma	2.74e-06	5.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—sarcoma	2.7e-06	5.32e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—sarcoma	2.66e-06	5.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—sarcoma	2.65e-06	5.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—sarcoma	2.59e-06	5.12e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—sarcoma	2.59e-06	5.11e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO2—sarcoma	2.49e-06	4.92e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HBA1—sarcoma	2.48e-06	4.89e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—sarcoma	2.48e-06	4.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MDM2—sarcoma	2.42e-06	4.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—sarcoma	2.42e-06	4.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—sarcoma	2.42e-06	4.77e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—sarcoma	2.41e-06	4.75e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—sarcoma	2.36e-06	4.66e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—sarcoma	2.26e-06	4.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—sarcoma	2.25e-06	4.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—sarcoma	2.23e-06	4.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—sarcoma	2.16e-06	4.27e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLCG1—sarcoma	2.12e-06	4.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—sarcoma	2.11e-06	4.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—sarcoma	2.11e-06	4.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—sarcoma	2.09e-06	4.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—sarcoma	2.06e-06	4.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—sarcoma	1.9e-06	3.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—sarcoma	1.89e-06	3.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—sarcoma	1.84e-06	3.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—sarcoma	1.82e-06	3.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—sarcoma	1.69e-06	3.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—sarcoma	1.56e-06	3.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—sarcoma	1.39e-06	2.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—sarcoma	1.33e-06	2.62e-05	CbGpPWpGaD
